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Section 1:  Administrative information 
1.1 HEAP administrative information 
Title Health Economics Analysis Plan (HEAP) for a  
randomised controlled trial of the STAR 
programme. A multi-centre randomised 
controlled trial to evaluate  a care pathway for 
patients with long-term pain after knee 
replacement. 
Trial registration number; registry ISRCTN registry (ISRCTN92545361), prospectively 
registered on 30 August 2016. 
Source of funding National Institute for Health Research (NIHR) 
Biomedical Research Centre at the University 
Hospitals Bristol NHS Foundation Trust and the 
University of Bristol. 
Purpose of HEAP The purpose of the HEAP is to describe the 
analysis and reporting procedure intended for the 
economic analyses to be undertaken. The analysis 
plan is designed to ensure that there is no conflict 
with the protocol and associated SAP, and it 
should be read in conjunction with them. 
Trial protocol version; date This document has been written based on 
information contained in the trial protocol version 
9, 04/02/2019 
Trial Statistical Analysis Plan (SAP) 
version, date 
2.2, 11/06/2019  
Trial HEAP version, date 1.0, 01/04/2020 
HEAP revisions n/a 
Roles and responsibilities  The HEAP was drafted by Dr Aideen Ahern (Junior 
HE: who has since left) and finalised and approved 
by Dr Sian Noble (Senior HE). The trial health 
economists Shaun Harris and Sian Noble are 
responsible for conducting and reporting the 
economic evaluation in accordance with the 
HEAP. 
APPROVALS 
The following people have reviewed the Health Economics Analysis Plan and are in 
agreement with the contents. 
Role Name Signature Date 
Lead Health 
Economist 
Dr Sian Noble  23/06/2020 
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1.2 Glossary of terms and abbreviations 
BPI Brief Pain Inventory 
HCHSI Hospital and Community Health Services Index  
HE Health Economist 
HEAP Health Economics Analysis Plan 
ICECAP-A ICEpop CAPability measure for Adults 
ICER Incremental Cost-Effectiveness Ratio 
ISRCTN International Standard Randomised Controlled Trial Number 
ITT Intention To Treat 
MAR Missing At Random 
MI Multiple Imputation 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
NMB Net Monetary Benefit 
OKS Oxford Knee Score 
PMM Predictive mean matching 
PSS Personal Social Services 
QALYs Quality Adjusted Life Years 
SAP Statistical Analysis Plan 
SD Standard Deviation 
STAR Support for treatment after joint replacement 
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Section 2: Trial introduction and background 
2.1 Trial background and rationale 
Total knee replacements aim to reduce pain, functional limitations and associated disability  
for those suffering from osteoarthritis. In the United Kingdom (UK) over 100,000 total knee 
replacements were performed in 20151 2 and approximately 20% of patients experience 
chronic pain after total knee replacement3. There is little evidence for interventions for the 
management of this pain, and current healthcare provision is patchy and inconsistent. Given 
the complexity of this condition, multimodal and individualised interventions matched to pain 
characteristics are needed. To improve the management of chronic pain after total knee 
replacement, the STAR (Support and Treatment After joint Replacement) care pathway was 
developed4. The aim of this multi-centre randomised controlled trial is to evaluate the clinical 
and cost-effectiveness of the care pathway for patients with chronic pain after total knee 
replacement. 
2.2 Aim of the trial 
Briefly, the STAR trial aims to evaluate the clinical effectiveness of a new care pathway when 
compared with usual care for people with chronic pain after knee replacement.  
2.3 Objectives of the trial 
The primary objective of the trial is to assess whether there is a clinically important 
difference, using the Brief Pain Inventory (BPI) pain score, of a new care pathway when 
compared with usual care for people with chronic pain after knee replacement.  
2.4 Trial population 
Inclusion criteria: Patients aged 18 years and over who have received a primary total knee 
replacement because of osteoarthritis at a participating National Health Services (NHS) Trust 
and who report pain in their operated knee at 2–3 months after surgery (score of 0–14 on 
the Oxford Knee Score (OKS) pain subscale5). 
Exclusion criteria: A lack of capacity to provide informed consent to participate, previous 
participation in the STAR trial for the contralateral knee, participation in another research 
study that interferes unacceptably with the STAR trial. Patients unable to complete study 
questionnaires in English or Welsh, and those unable to be contacted by telephone. 
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2.5 Intervention and comparator 
Intervention: one-hour STAR assessment clinic with an Extended Scope Practitioner to identify 
potential causes of pain and enable onwards referral to appropriate existing services. Up to 6 
telephone follow-up calls from the Extended Scope Practitioner over the 12-month follow-up 
period. 
Comparator: care as usual as provided by the patient’s hospital consisting of either routine 
follow-up only at six weeks post-operative. One centre provides an additional three-month 
appointment. All centres provide additional follow-up with a surgeon if requested but do not 
include follow-up by practitioners specialising in pain. 
2.6 Trial design 
This is a pragmatic, parallel, two-arm, multi-centred randomised controlled trial using 2:1 
intervention: control randomisation, with an internal pilot phase and embedded economic 
evaluation and qualitative studies. The trial is currently taking place at 8 NHS secondary care 
centres across the UK. 
2.7 Trial start and end dates 
Recruitment started in October 2016 and is due to finish July 2019. The follow-up period will 
run for 12 months until July 2020. 
Section 3: Economic approach 
3.1 Aim of economic evaluation 
The health economic analysis with consist of a within-trial analysis of the cost-effectiveness 
of a new care pathway for patients with long-term pain after knee replacement. 
3.2 Objectives of economic evaluation 
The primary objective of the health economic evaluation is to estimate the short-term cost-
effectiveness of The STAR pathway compared to usual care. 
3.3 Overview of economic analysis 
The within trial economic analysis from both an NHS and PSS and wider perspective (to 
include patient costs) will be performed using individual patient level data from the STAR 
trial. The primary economic analysis will compare the difference in NHS and PSS costs relating 
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to the treatment of long-term pain with the difference in QALYS. Wider societal costs 
including opportunity costs incurred by the patient or family members will not be included 
within the cost-effectiveness analysis.  
3.4 Jurisdictions 
The trial is conducted in the UK, which has a National Health Services (NHS), providing 
publicly funded healthcare, primarily free of charge at the point of use. 
3.5 Perspective 
The primary cost-effective analysis will take an NHS and Personal Social Services (PSS) 
perspective. A secondary analysis will take a broader perspective to include patients’ costs. 
3.6 Time horizon 
The primary economic analysis will compare the costs and effects of each arm 12 months 
after randomisation. 
Section 4: Economic data collection and management 
4.1 Statistical software 
Stata version 15.1 or higher will be used for all economic analyses. 
4.2 Identification of resources 
Only resources used in relation to chronic pain on the operated knee will be measured from 
randomisation to 12 months follow-up. The following items of resource use that may differ 
between arms will be measured: resources used in relation to the intervention, health service 
resource use, personal social services and personal expenditure related to the chronic pain 
and its treatment e.g. travel, non-prescribed medications, special equipment.  
4.3 Measurement of resource use data 
The costs relating to the intervention will be determined by calculating the costs of staff time 
and any resources and materials used in providing the STAR treatment pathway. This includes 
any resources associated with training, delivery and administration for face-to-face 
assessments and telephone contacts, but excludes any costs associated with research which 
would not be a component of the delivery of the STAR intervention in a standard clinical 
setting. Resources used will be recorded on a standardised proforma. 
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Resource use data including inpatient stays and outpatient visits for all patients at the 
treating hospitals will be obtained from hospital electronic systems. Use of health services 
including primary and community care, use of personal social services and additional costs 
will be collected in the participant completed follow-up questionnaires at 6 and 12 months 
after randomisation. Participants can choose to complete a paper or an online version and 
will receive a questionnaire through the post or an email link as appropriate.  Participants are 
provided with resource diaries and prescribed medication folders to prospectively record and 
document any health resources they have used, to assist them in the completion of the 
questionnaires.  
4.4 Valuation of resource use data 
All resources will be valued in monetary terms using appropriate UK unit costs or participant 
valuation estimated at the time of analysis. NHS reference costs will be employed to value 
hospital resource use and intervention costs. Medications will be valued using the British 
National Formulary (BNF) or Prescription Cost Analysis (PCA) for England.  Primary Care 
consultations and any other community-based health care services will be mainly costed 
using Curtis ‘Unit Costs of Health & Social Care6. Costs directly reported in the Resource Use 
Questionnaires will be used to value out-of-pocket expenditures related to the patient’s 
urinary symptoms and any associated treatment (e.g. over the counter medications). Paid 
time off work will be costed using the Office of National Statistics (ONS) information on 
salaries.  (see Table 1 for more details) 
When a unit cost is not available for the year of analysis, an upgrade will be made using the 
appropriate method of inflation (e.g. NHS cost inflation index (NHSCII)). 
 
4.5 Identification of outcomes 
The primary economic outcome measure will be the Quality Adjusted Life Years (QALYs) 
derived from utility scores, obtained using the EQ-5D-5L7 quality of life instrument.  
Secondary outcomes for the economic evaluation will include the effectiveness co-primary 
outcomes of BPI pain score and OKS in addition to ICEpop CAPability measure for Adults 
(ICECAP-A)8 and the Short Form-12 (SF-12)9. 
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4.6 Measurement of outcomes 
Outcomes will be collected at baseline, 6- and 12- months post randomisation. using a 
participant self-completed questionnaire, which can be completed online or on paper, using 
a postal questionnaire or an email link as appropriate. 
4.7 Follow-up of non-responders 
Participants who have not returned their questionnaires after their two-week reminder are 
offered the option of completing the questionnaires over the phone, and in some cases are 
offered a home visit. Telephone calls to patients who do not return a follow-up questionnaire 
will be performed by a researcher from a different trial centre to ensure that the researcher 
is blinded to treatment allocation 
4.7 Valuation of outcomes 
Utility values will be derived from response to the EQ-5D-5L. They will be derived using the 
approach recommended by National Institute for Health and Care Excellence (NICE)10. NICE 
currently advises that the 5-level valuation set for England is not recommended for use to 
derive utilities, instead advising that the validated mapping function to the 3-level valuation 
set be used for reference-case analysis. These will be used to form QALYs over the 12-month 
period, adjusting for any imbalances in baseline EQ-5D-5L scores. 
Section 5: Economic data analysis 
5.1 Analysis population 
It is intended that all participants randomised into the trial will be analysed as per their 
randomisation group in accordance with a modified intention to treat (ITT) principle (i.e. all 
randomised participants who provided outcome data).  
5.2 Timing of analyses 
The primary analysis will be conducted once all patients have been followed up for 12 
months from randomisation 
5.3 Discount rates for costs and benefits 
There will be no discounting of costs or effects given the 1-year duration of the study. 
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5.4 Cost-effectiveness threshold 
 The primary economic analysis will use a cost-effectiveness threshold of £20,000 per QALY11. 
5.5 Data cleaning for analysis 
Face validity tests will be conducted on data (e.g. to identify misspelt text) and checked 
against the source documents. Corrections identified will be documented in the Stata code. 
5.6 Missing data 
Missing data may relate to item non-response, where a questionnaire is partially incomplete, 
or unit non-response where all the information is missing. 
Item non-response on the EQ-5D-5L™ questionnaire will not be individually imputed; instead 
the questionnaire will be treated in the same manner as those which are fully incomplete 
with QALYs imputed with unit non-response procedures (e.g. multiple imputation).  
Baseline covariates will be imputed in accordance with the statistical analysis. Imputation at 
baseline will allow for all participants to be included in the analysis of the outcome score; 
simple imputation methods are considered superior when baseline values are included in an 
adjusted analysis to improve the precision of the treatment effect (White and Thompson, 
2005). This imputation will only be considered for the regression analysis and not for 
summarising baseline scores. 
The resource use questionnaire asks patients to record the health services they have used 
and anything they have had to buy directly because of the pain they have experienced in 
their replaced knee. It consists of five sections: use of health care services, travel to services, 
use of medications, home changes and home care, and time off work. Item non-response 
within this questionnaire may represent either the individual failing to record a non-zero 
value, or alternatively left incomplete to represent no contact. For each part, if one or more 
questions are at least partially complete, any fully incomplete questions will be assumed to 
represent no contact or usage of that type.  
The pattern of missing outcome and resource data, after implementation of item-non-
response procedures outlined above, will be examined. The appropriate method for dealing 
with missing data will depend on the prevalence of missing data and likely mechanism of 
missingness. If the data is missing at random (MAR)12(missingness dependent upon observed 
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data but not the unobserved outcomes), multiple imputation using chained equations will be 
used to impute missing items to provide an unbiased analysis on all randomised individuals.  
Imputations will be combined following Rubin’s rules (Rubin, 1987). Due to the predefined 
range of outcome scores, including utility derived from the EQ-5D-5L™ and the typically 
skewed distribution of costs data, predictive mean matching (PMM) will be used to ensure 
imputed values are consistent with observed data.  The plausibility of the MAR assumption 
will be explored by comparing observed data in participants with and without the item of 
interest and further sensitivity analyses will explore the robustness of conclusions should 
outcomes be assumed to be missing not at random (MNAR). 
5.7 Analysis of costs 
The mean resource use and costs will be estimated and presented by trial arm for each 
resource use category (e.g. outpatient visits, medication use, etc.). Standard deviations (SD) 
and the number of patients included in each category by arm will also be presented.  
Appropriate regression techniques e.g. SUR will be used to estimate adjusted mean costs and 
the difference in adjusted mean costs (and their associated 95% confidence intervals) 
between the trial arms in relation to NHS and PSS costs and in relation to NHS, PSS and 
patient costs. The regression will be adjusted for the minimisation variables of the 
randomisation process (the Brief Pain Inventory Severity and Interference Scales), and the 
stratification variable (orthopaedic centre). 
5.8 Analysis of outcomes 
The primary economic outcome in STAR is the QALY. QALYs for each patient over the 12-
month period will be calculated from the utility values using the area under the curve 
approach, and this will consider any deaths that have occurred during the duration of the 
study.  
Appropriate regression techniques e.g. SUR will be used to estimate adjusted mean QALYs 
and the difference in adjusted mean QALYs (and their associated 95% confidence intervals) 
between the trial arms. The regression will be adjusted for baseline utility, the minimisation 
variables of the randomisation process (the Brief Pain Inventory Severity and Interference 
Scales), and the stratification variable (orthopaedic centre). 
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BPI pain score, OKS, ICECAP-A and SF-12 which will be used for the cost-consequence analysis 
will be estimated as outlined in the SAP. 
5.9 Analysis of cost-effectiveness 
 
Primary Economic analysis (NHS and PSS perspective) and Secondary Economic analysis (NHS, 
PSS, and patient perspective) 
  
Taking each perspective in turn, if neither intervention is dominant (i.e. less expensive and 
more effective), incremental cost-effectiveness ratios will be created using the outputs from 
the appropriate regression. These outputs will also be used to estimate the incremental net 
monetary benefit (INMB) statistic at the standard NICE willingness to pay threshold of 




A cost consequence analysis will be conducted in which mean adjusted costs and outcomes 
(OKS, BPI pain score, ICECAP-A and SF-12) are displayed in tabular form. 
 
5.10 Subgroup analyses 
Analyses will also be conducted on the final dataset to investigate how cost-effectiveness 
varies between different patient subgroups.  Three subgroup analyses will be conducted. 
1) An analysis on the primary economic outcome from the NHS and PSS perspective will 
be performed by including appropriate interaction terms between the intervention 
group and other patient characteristics in the regression models, to investigate any 
differential effects in certain subgroups of the population. These factors will be trial 
centre and baseline Oxford Knee Score. 
2) An analysis will be performed for those sites who limit patients who are less than 1 
hour drive away versus those who accept all patients regardless of the distance from 
site. 
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3) An analysis will be performed in which patients who completed follow-up prior to 
March 23rd 2020 (the start of the UK lockdown due to Covid-19) will be compared to 
those who completed follow-up on or after this date. 
5.11 Sampling uncertainty 
Uncertainty will be addressed using cost-effectiveness acceptability curves for a range of 
willingness-to-pay thresholds. For multiple feasible WTP thresholds, the probability of cost-
effectiveness will be explicitly highlighted. 
5.12 Sensitivity analyses 
Sensitivity analyses will be undertaken to explore methodological uncertainty in the 
economic evaluation. Issues may arise in the cleaning and analysis which may mean more 
analyses than the one specified will be included.   
The results for complete cost and quality of life data (i.e. those with no missing data) 
will be provided to identify the impact of missing data on the analysis. 
Section 6: Reporting/publishing  
6.1 Reporting standards  
CHEERS guidelines15 will be followed when reporting the health economic evaluation, in a 
format appropriate to stakeholders and policy makers.  
6.2 Deviations from the HEAP  
Any deviation from HEAP will be described and justified in the final published report.  
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Table 1 Resource use sources  
Resource Source of cost 
NHS inpatient stays NHS reference costs 
Outpatient visits NHS reference costs 
A& E visits/admissions NHS reference costs 
Intervention appointment and phone calls   NHS reference costs & Lesley Curtis PSSRU 
Prescriptions British National Formulary/ Prescription Costs Analysis England 
Appointment with a GP at the GP practice Lesley Curtis PSSRU 
Home visit with a GP Lesley Curtis PSSRU 
Telephone call with a GP Lesley Curtis PSSRU 
Appointment with a GP practice nurse at the GP 
practice Lesley Curtis PSSRU 
Telephone call with a GP practice nurse Lesley Curtis PSSRU 
Home visit from a district nurse Lesley Curtis PSSRU 
NHS 111 or NHS direct Wales telephone call Lesley Curtis PSSRU 
Appointment with an NHS physiotherapist at a health 
centre/GP practice Lesley Curtis PSSRU 
Appointment with a private physiotherapist Lesley Curtis PSSRU 
Appointment for NHS acupuncture (not in a hospital) Lesley Curtis PSSRU 
Appointment for private acupuncture web-based resources 
Appointment for private hydrotherapy web-based resources 
Community-based urology service Lesley Curtis PSSRU 
Other NHS community care visit Lesley Curtis PSSRU 
Paid time off work Office of National Statistics (ONS) 
Home changes and home care Patient self-reported, web-based resources 
Home care worker Patient self-reported, Lesley Curtis PSSRU 
Over the counter medication Patient self-reported, web-based resources 
Other expenses Patient self-reported, web-based resources 
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Table 2 Example of how resource use may be presented 








(£)  (SD) 





Intervention appointment (number)       
Intervention phone calls (number)       
Inpatient stays (number of nights)       
Outpatient appointments (number of 
appointments) 
      
A&E visits/admissions (number of 
admissions) 
      
Appointment with a GP at the GP 
practice (number of appointments) 
      
Home visit with a GP (number of 
visits) 
      
Telephone call with a GP (number of 
calls) 
      
Appointment with a GP practice 
nurse at the GP practice (number of 
appointments) 
      
Telephone call with a GP practice 
nurse (number of calls) 
      
Home visit from a district nurse  
(number of visits) 
      
NHS 111 or NHS Direct Wales 
telephone call (number of calls) 
      
Appointment with an NHS 
physiotherapist at a health centre/GP 
practice (number of appointments) 
      
Appointment with a private 
physiotherapist (number of 
appointments) 
      
Appointment for NHS acupuncture  
(number of appointments) 
      
Appointment for private acupuncture 
(number of appointments) 
      
Appointment for private 
hydrotherapy (number of 
appointments) 
      
Other primary or community care 
contacts (number of contacts) 
      
Prescriptions (number of 
prescriptions) 
      
Home care worker (number of hours)       
Paid Time off work (number of hours)       
Travel costs (number of journeys)       
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Over-the-counter medication 
(number of medications) 
      
Any other costs (number of items)       
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Table 3. Example of how the main economic analyses may be presented 
Allocation 
arm 
















NMB (£) at 
£20000/QALY 
(95% CI) 
NHS and PSS Costs 
Intervention        
Usual Care        
Patient Costs 
Intervention        
Usual Care        
Total Costs        
Intervention        
Usual Care        
 
 
Table 4. Example of how the Cost consequence analysis may be presented 
Variable N (I:UC) 
Adj. Intervention Adj. Usual Care Adj. difference in 
Mean (95% C.l.) Mean (95% C.l.)  means (95% C.l.) 
QALY     
BPI     
OKS     
ICECAP-A     
SF-12     
NHS & PSS costs   
   
Patient costs  
   
Total costs  
   
(I=Intervention, UC=Usual Care) 
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Table 5. Example of how the economic sensitivity analyses maybe presented 
Allocation 
arm 
















NMB (£) at 
£20000/QALY 
(95% CI) 
Sensitivity Analyses 1: Different ways of dealing with missing data 
Intervention        
Usual Care        
Sensitivity Analyses 2: Complete Case/Imputed  
Intervention        
Usual Care        
Sensitivity Analyses 3: XXX 
Intervention        
Usual Care        
Sensitivity Analyses 4: XXX 
Intervention        
Usual Care        
(Above are examples, repeat as many times number of sensitivity analyses performed) 
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